XML 68 R48.htm IDEA: XBRL DOCUMENT
v3.26.1

Basis of Presentation - Summary of Subsidiaries which are Wholly Owned and Subject to Control (Details) | 12 Months Ended
--- | ---
Apr. 30, 2026 | Apr. 30, 2025 | Apr. 30, 2024
ImmunoPrecise Antibodies (Canada) Ltd. d/ba/ MindWalk Biologics |  |  |
Disclosure Of Significant Investments In Subsidiaries [Line Items] |  |  |
Name of Subsidiary | ImmunoPrecise Antibodies (Canada) Ltd. d/ba/ MindWalk Biologics |  |
Equity Interest percentage | 100.00% | 100.00% | 100.00%
Country of Incorporation | Canada |  |
Functional Currency | Canadian dollar |  |
ImmunoPrecise Antibodies (USA) Ltd. ("IPA USA") |  |  |
Disclosure Of Significant Investments In Subsidiaries [Line Items] |  |  |
Name of Subsidiary | ImmunoPrecise Antibodies (USA) Ltd. ("IPA USA") |  |
Equity Interest percentage | 100.00% | 100.00% | 100.00%
Country of Incorporation | USA |  |
Functional Currency | U.S. dollar |  |
ImmunoPrecise Antibodies (N.D.) LTD |  |  |
Disclosure Of Significant Investments In Subsidiaries [Line Items] |  |  |
Name of Subsidiary | ImmunoPrecise Antibodies (N.D.) LTD |  |
Equity Interest percentage | 100.00% | 100.00% | 100.00%
Country of Incorporation | USA |  |
Functional Currency | U.S. dollar |  |
ImmunoPrecise Antibodies (MA) LLC |  |  |
Disclosure Of Significant Investments In Subsidiaries [Line Items] |  |  |
Name of Subsidiary | ImmunoPrecise Antibodies (MA) LLC |  |
Equity Interest percentage | 100.00% | 100.00% | 100.00%
Country of Incorporation | USA |  |
Functional Currency | U.S. dollar |  |
Talem Therapeutics LLC ("Talem") |  |  |
Disclosure Of Significant Investments In Subsidiaries [Line Items] |  |  |
Name of Subsidiary | Talem Therapeutics LLC ("Talem") |  |
Equity Interest percentage | 100.00% | 100.00% | 100.00%
Country of Incorporation | USA |  |
Functional Currency | U.S. dollar |  |
ImmunoPrecise Netherlands B.V. |  |  |
Disclosure Of Significant Investments In Subsidiaries [Line Items] |  |  |
Name of Subsidiary | ImmunoPrecise Netherlands B.V. |  |
Equity Interest percentage | 100.00% | 100.00% | 100.00%
Country of Incorporation | Netherlands |  |
Functional Currency | Euro |  |
ImmunoPrecise Antibodies (Europe) B.V. ("IPA Europe") |  |  |
Disclosure Of Significant Investments In Subsidiaries [Line Items] |  |  |
Name of Subsidiary | ImmunoPrecise Antibodies (Europe) B.V. ("IPA Europe") |  |
Equity Interest percentage | 0.00% | 100.00% | 100.00%
Country of Incorporation | Netherlands |  |
Functional Currency | Euro |  |
BioStrand B.V. d/b/a MindWalk |  |  |
Disclosure Of Significant Investments In Subsidiaries [Line Items] |  |  |
Name of Subsidiary | BioStrand B.V. d/b/a MindWalk |  |
Equity Interest percentage | 100.00% | 100.00% | 100.00%
Country of Incorporation | Belgium |  |
Functional Currency | Euro |  |
Idea Family BV |  |  |
Disclosure Of Significant Investments In Subsidiaries [Line Items] |  |  |
Name of Subsidiary | Idea Family BV |  |
Equity Interest percentage | 100.00% | 100.00% | 100.00%
Country of Incorporation | Belgium |  |
Functional Currency | Euro |  |
BioKey BV |  |  |
Disclosure Of Significant Investments In Subsidiaries [Line Items] |  |  |
Name of Subsidiary | BioKey BV |  |
Equity Interest percentage | 100.00% | 100.00% | 100.00%
Country of Incorporation | Belgium |  |
Functional Currency | Euro |  |
BioClue BV |  |  |
Disclosure Of Significant Investments In Subsidiaries [Line Items] |  |  |
Name of Subsidiary | BioClue BV |  |
Equity Interest percentage | 100.00% | 100.00% | 100.00%
Country of Incorporation | Belgium |  |
Functional Currency | Euro |  |

X
- Definition The country in which a subsidiary of the entity is incorporated. [Refer: Total for all subsidiaries [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2025-01-01 -Paragraph 16 -Subparagraph b -Clause ii -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_16_b_ii&doctype=Standard -URIDate 2025-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2025-01-01 -Paragraph 17 -Subparagraph b -Clause ii -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_17_b_ii&doctype=Standard -URIDate 2025-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2025-01-01 -Paragraph 12 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_12_b&doctype=Standard -URIDate 2025-03-27 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2025-01-01 -Paragraph 19B -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_19B_b&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The description of the currency of the primary economic environment in which the entity operates. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 21 -IssueDate 2025-01-01 -Paragraph 53 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_53&doctype=Standard -URIDate 2025-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 21 -IssueDate 2025-01-01 -Paragraph 57 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_57_c&doctype=Standard -URIDate 2025-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Note Effective 2027-01-01 -Name IFRS -Number 19 -IssueDate 2025-01-01 -Paragraph 219 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_219&doctype=Standard -URIDate 2025-03-27 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Note Effective 2027-01-01 -Name IFRS -Number 19 -IssueDate 2025-01-01 -Paragraph 219 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_219&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_DescriptionOfFunctionalCurrency
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The name of a subsidiary. [Refer: Total for all subsidiaries [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2025-01-01 -Paragraph 17 -Subparagraph b -Clause i -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_17_b_i&doctype=Standard -URIDate 2025-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2025-01-01 -Paragraph 12 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_12_a&doctype=Standard -URIDate 2025-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2025-01-01 -Paragraph 16 -Subparagraph b -Clause i -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_16_b_i&doctype=Standard -URIDate 2025-03-27 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2025-01-01 -Paragraph 19B -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_19B_a&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_NameOfSubsidiary
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Total for all subsidiaries [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2025-01-01 -Paragraph 17 -Subparagraph b -Clause iii -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_17_b_iii&doctype=Standard -URIDate 2025-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2025-01-01 -Paragraph 16 -Subparagraph b -Clause iii -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_16_b_iii&doctype=Standard -URIDate 2025-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2025-01-01 -Paragraph 19B -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_19B_c&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_ProportionOfOwnershipInterestInSubsidiary
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=hyft_ImmunoPreciseAntibodiesCanadaLtdDBaMindWalkBiologicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=hyft_ImmunoPreciseAntibodiesUSALtdIPAUSAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=hyft_ImmunoPreciseAntibodiesNDLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=hyft_ImmunoPreciseAntibodiesMALLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=hyft_TalemTherapeuticsLLCTalemMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=hyft_ImmunoPreciseNetherlandsBVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=hyft_ImmunoPreciseAntibodiesEuropeBVIPAEuropeFormerlyModiQuestResearchBVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=hyft_BioStrandBVDBAMindWalkMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=hyft_IdeaFamilyBVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=hyft_BioKeyBVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=hyft_BioClueBVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |